Ruben Niesvizky, MD, explains Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities at Imedex Great Debates 2018.
Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib
Paul G. Richardson, MD, explains Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib at Imedex Great Debates 2018.
One Size Does Not Fit All in Myeloma Clonal Tiding & Complex Heterogeneity
Paul G. Richardson, MD, explains Combinations with RVD Beyond Daratumumab Data with ixazomib, revlimid, & dexamethasone at Imedex Great Debates 2018.
RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids
Paul G. Richardson, MD, explains RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids at Imedex Great Debates 2018.
Selinexor is a Novel Mechanism of Action Venetoclax Serves a Challenging Population
Paul G. Richardson, MD, explains Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities at Imedex Great Debates 2018.
Powerful new IMiDs, CC-220 & CC-92480 Importance of Small Molecules in advanced trials
Paul G. Richardson, MD, explains Powerful new IMiDs, CC-220 & CC-92480 Importance of Small Molecules in advanced trials at Imedex Great Debates 2018.
Melflufen is a Modified Derivative of Melphalan Peptidase-avid and a targeted form of chemotherapy
Paul G. Richardson, MD, explains Melflufen is a Modified Derivative of Melphalan Peptidase-avid and a targeted form of chemotherapy at Imedex Great Debates 2018.
Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity
Paul G. Richardson, MD, explains Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity at Imedex Great Debates 2018.